White Paper
COVID-19 Recession Effects On Pharmaceutical-Related Patient Health Outcomes
This white paper investigates the research framework to model the expected effects on the decline in health outcomes caused by a decrease in the quantity and quality of pharmaceuti ...
White Paper
Designing A Patient-Centric Commercial Strategy
This whitepaper addresses how RWE should be leveraged for informing various commercial decisions with a deeper-dive into marketing-mix analysis (MMx). ...
Blog
Quantifying The Economic Burden Of Inadequate Symptom Control Among Patients With IBS-D
Axtria recently collaborated on a study to analyze the “Economic burden of inadequate symptom control among US commercially insured patients with irritable bowel syndrome wit ...
Blog
Insightful HEOR Analysis For The Cardiovascular Community
Some of the most rewarding work we are involved in at Axtria right now is in the Health Economics and Outcomes Research (HEOR) space, where we are partnering with our clients to ...
Blog
Quantifying The Economic Burden Of IBS-D
As the industry shifts from volume to value based models, it is becoming necessary for Pharmaceutical companies to demonstrate the value their brands deliver through outcomes and e ...
Blog
Implications From HEOR And RWE Models For Biopharmaceutical Commercial Analytics
The following blog is an expanded summary of proposed research accepted for delivery at the upcoming 22nd ISPOR Annual International Meeting, Research Poster Presentations – ...
White Paper
The Relationship Between Drug Price Controls And Patient Health Outcomes
No long-term “solution” on drug pricing has emerged gaining broad consensus among public policy officials and politicians, patient advocacy groups, medical and health service r ...
White Paper
Deploying K-Nearest Neighbor Modeling Methodologies For Real World Problems
There has been an immense improvement of theory and algorithms in recent times leading to enhancement in computation power. Also, online data availability was never easier than now ...
